BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:NST-628 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of NST-628\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07784985-2643@assetmemo.bio
DTSTAMP:20261121T005441Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:NST-628: Phase 1 readout est. (NCT07784985)
DESCRIPTION:NST-628\, phase 1.\nStudy: A Study of NST-628 in Recurrent Grad
 e 4 Glioma\nEstimated primary completion: July 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/nst-628#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07784985
URL:https://assetmemo.bio/drug/nst-628#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06326411-2643@assetmemo.bio
DTSTAMP:20261121T005441Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:NST-628: Phase 1 readout est. (NCT06326411)
DESCRIPTION:NST-628\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A Study
  to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subject
 s With Solid Tumors\nEstimated primary completion: November 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/nst-628#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06326411
URL:https://assetmemo.bio/drug/nst-628#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
